Abstract:In this study, initiated in 2009, quiescent infections of African Elephant Endotheliotropic Herpesviruses (EEHVs) EEHV2, EEHV3A, EEHV3B, EEHV6, EEHV7A and EEHV7B, that can cause lethal Elephant Hemorrhagic Disease (EHD) and African Elephant Gammaherpesviruses (EGHVs) EGHV1B, EGHV2, EGHV3B, EGHV4B and EGHV5B, that are not associated with severe morbidity, were detected in African elephants, Loxodonta africana and Loxodonta cyclotis, in Africa and USA. We genetically evaluated trunk fibropapillomas (nodules), saliva, blood and tissues collected from 43 wild Loxodonta africana (African savannah elephants) in Botswana, Kenya and South Africa; saliva received from 25 wild Loxodonta cyclotis (African forest elephant) in Gabon; and saliva collected over a seven year period from 7 wild-born Loxodonta africana (6 from Uganda and 1 from Zimbabwe) residing in Six Flags Safari Park in Jackson, NJ, USA, and saliva, blood and tissues collected from an additional 200 Loxodonta africana and 100 Elephas maximus (Asian elephant) in USA. DNA was extracted and amplified by conventional PCR (cPCR) using three-round nested primer sets targeting many African Elephant EEHVs genes loci and primers designed specifically to recognize African Elephant EGHVs species. Sanger sequencing yielded unambiguous positive genetic matches to known African Elephant EEHV2, EEHV3A, EEHV6, EEHV7A, EGHV1B, EGHV2, EGHV3B, EGHV4B, EGHV5B and discovered novel species including EEHV3B, rare subtypes EEHV3C to EEHV3H and EEHV7B, and the prototype African Elephant EGHV1B. Our extensive library of elephant viral sequences and genomic DNA samples are invaluable assets for development of vaccines against EHD and for conserving genomic diversity in dwindling herds in situ and isolated herds in preserves and zoos worldwide.

What problem does this paper attempt to address?

The main problems that this paper attempts to solve are to detect and identify the Endotheliotropic Elephant Herpesviruses (EEHVs) and Elephant Gammaherpesviruses (EGHVs) with latent infections in African elephants (including African savanna elephants *Loxodonta africana* and African forest elephants *Loxodonta cyclotis*). These viruses can cause fatal Elephant Hemorrhagic Disease (EHD), especially subtypes such as EEHV2, EEHV3A, EEHV3B, EEHV6, EEHV7A and EEHV7B. In addition, the study also focused on subtypes such as EGHV1B, EGHV2, EGHV3B, EGHV4B and EGHV5B that are not related to severe diseases. Specifically, the study aims to: 1. **Detect latent infections**: By analyzing different samples (such as fibropapillomas, saliva, blood and tissues) from Africa and the United States, determine whether there are latent infections of the above - mentioned herpesviruses. 2. **Discover new virus subtypes**: Through gene sequencing of samples, new EEHV and EGHV subtypes were discovered, such as EEHV3B, EEHV3C to EEHV3H and EEHV7B, and the existence of the prototype African elephant EGHV1B was confirmed. 3. **Provide a basis for vaccine development**: By establishing extensive virus sequence libraries and genomic DNA sample libraries, it provides valuable resources for the future development of vaccines against EHD, and at the same time helps to protect the genetic diversity of elephant populations in the wild and in zoos. In summary, the core objective of this study is to reveal the latent herpesvirus infection situation in African elephants through detailed genetic analysis, and provide a scientific basis for disease prevention and control.

Quiescent Infections of Elephant Endotheliotropic Herpesviruses and Elephant Gammaherpesviruses in African Elephants in Botswana, Gabon, Kenya, South Africa and USA